Global Biopharmaceutical Market Report (2010-2015)

The Global Biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. Today more than three hundred biopharmaceuticals have already been approved and many more are in late stage clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases, but have also provided the thrust for the continued success of the pharmaceutical industry.

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition and out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry’s US$ 92 Billion figures and double digit growth rates in the last five years are a testimonial to the fact that the ones that finally do get approval represent goldmines for investors.

Although factors such as biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, the authors expect that the high potency and ability of biopharmaceuticals to attack targets beyond the reach of traditional small molecule drugs gives the industry a huge scope for future growth. A rich late stage pipeline and the growth of emerging markets are also expected to be major drivers for growth in the next five years. IMARC expects the global biopharmaceutical market to reach level of sales figures worth more than US$ 167 Billion by 2015.

“Global Biopharmaceutical Market Report (2010-2015)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2015. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in some form or the other.

Report Highlights

- Biopharmaceuticals enjoy a higher approval success rate compared to traditional small molecule drugs. They, however, require higher investments and take longer development times.

- Biopharmaceuticals are significantly more expensive than traditional medications, with the annual cost of therapy of some biopharmaceuticals touching more than a hundred thousand dollars a year. The cost of these drugs, however, is expected to be closely scrutinized by payers in the coming years.

- Recombinant Proteins represented the biggest biopharmaceutical class in 2009, accounting for more than 65% of the total global biopharmaceutical sales. Growth in this class is expected to be low in most of the developed markets as a result of biosimilar entry and increasing cost containment measures.

- Monoclonal Antibodies are expected to be the biggest drivers of the biopharmaceutical market in the next five years. Driven by a rich late stage pipeline and a strong uptake from both developed and emerging market, Monoclonal Antibodies are expected to be worth more than US$ 79 Billion by 2015.

- Imarc expects the top eight markets (US, Germany, Japan, France, Italy, Spain, UK and Canada) to account for around 79% of the total global biopharmaceutical sales by 2015. This represents a decline of 4% over their 2009 share.

- The market share of emerging markets (Brazil, Russia, India, China, Mexico, Turkey and South Korea) is likely to increase from less than 5% in 2009 to more than 8% by 2015.

Regions/Countries Covered
Global, US, Germany, Japan, France, Italy, Spain, United Kingdom, Canada, Russia, China, Australia, Turkey, Mexico, South Korea, India, Brazil, Argentina and Indonesia.

Classes Covered for Each Region/Country
Recombinant Proteins, Insulin, Erythropoietins, Interferons, Colony Stimulating Factors, Immunoglobulins, Recombinant Blood Factors, Growth Hormones, Recombinant Enzymes, Interleukins, Growth Factors, Monoclonal Antibodies and Purified Proteins.

Key Features

- Analysis of the key strengths, weaknesses, opportunities and threats faced by the global biopharmaceutical market.

- Exhaustive in-depth individual analysis for eighteen major developed and emerging markets.

- 2005 to 2009 trend analysis for the global and 18 selected biopharmaceutical markets.

- 2005 to 2009 trend analysis for individual biopharmaceutical classes for the global and 18 selected biopharmaceutical markets.

- 2005 to 2009 trend analysis for the performance of top players for the global and 18 selected biopharmaceutical markets.

- 2010-2015 sales forecast for the global and 18 selected biopharmaceutical markets. SHOW LESS READ MORE >

1. Market Definitions & Research Methodology

2. Analyst Briefing

3. Introduction to Biopharmaceuticals

4. Global Biopharmaceutical Market: Industry Analysis
4.1 Strengths
4.1.1 High Efficacy and Target Oriented Attack
4.1.2 Strong Potential to Achieve Blockbuster Status
4.1.3 Limited Generic Threat
4.1.4 Approval Success Rates are Higher than Small Molecule Drugs
4.2 Weaknesses
4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives
4.2.2 Second Line of Therapy
4.2.3 Huge Cost of Therapy
4.2.4 High Incidence of Unfavorable Side Effects
4.3 Opportunities
4.3.1 Diseases with High Unmet Needs
4.3.2 Expanding the Patient Pool by Approval into Additional Indications
4.3.3 Emerging Markets
4.3.4 Increasing New Approvals and a Strong Pipeline
4.4 Threats
4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
4.4.2 Biosimilars
4.4.3 Limited and Conditional Reimbursement
4.4.4 Uncertainties in the Economic Environment

5. Global Biopharmaceutical Market: Industry Performance
5.1 Market Performance & Forecast
5.1.1 Current Performance (2005-2009)
5.1.2 Market Forecasts (2010-2015)
5.2 Market Segmentation by Region
5.2.1 Current Performance (2005-2009)
5.2.2 Market Forecasts (2010-2015)
5.3 Market Segmentation by Indication
5.4 Market Segmentation by Class
5.4.1 Recombinant Proteins
5.4.1.1 Current Performance (2005-2009)
5.4.1.2 Market Forecasts (2010-2015)
5.4.2 Monoclonal Antibodies
5.4.2.1 Current Performance (2005-2009)
5.4.2.2 Market Forecast (2010-2015)
5.4.3 Purified Proteins
5.4.3.1 Current Performance (2005-2009)
5.4.3.2 Market Forecast (2010-2015)
5.5 Competitive Landscape
5.5.1 Top Biopharmaceutical Players
5.5.2 Top Biopharmaceutical Drugs

6. North America
6.1 US
6.1.1 Market Performance (2005-2009)
6.1.2 Market Segmentation by Class
6.1.2.1 Recombinant Proteins
6.1.2.2 Monoclonal Antibodies
6.1.2.3 Purified Proteins
6.1.3 Performance of Top Players
6.1.4 Market Forecasts (2010-2015)
6.2 Canada
6.2.1 Market Performance (2005-2009)
6.2.2 Market Segmentation by Class
6.2.2.1 Recombinant Proteins
6.2.2.2 Monoclonal Antibodies
6.2.3 Performance of Top Players
6.2.4 Market Forecasts (2010-2015)

7. Latin America
7.1 Mexico
7.1.1 Market Performance (2005-2009)
7.1.2 Market Segmentation by Class
7.1.2.1 Recombinant Proteins
7.1.2.2 Monoclonal Antibodies
7.1.2.3 Purified Proteins
7.1.3 Performance of Top Players
7.1.4 Market Forecasts (2010-2015)
7.2 Brazil
7.2.1 Market Performance (2005-2009)
7.2.2 Market Segmentation by Class
7.2.2.1 Recombinant Proteins
7.2.2.2 Monoclonal Antibodies
7.2.2.3 Purified Proteins
7.2.3 Performance of Top Players
7.2.4 Market Forecasts (2010-2015)
7.3 Argentina
7.3.1 Market Performance (2005-2009)
7.3.2 Market Segmentation by Class
7.3.2.1 Recombinant Proteins
7.3.2.2 Monoclonal Antibodies
7.3.2.3 Purified Proteins
7.3.3 Performance of Top Players
7.3.4 Market Forecasts (2010-2015)

8. Europe
8.1 Germany
8.1.1 Market Performance (2005-2009)
8.1.2 Market Segmentation by Class
8.1.2.1 Recombinant Proteins
8.1.2.2 Monoclonal Antibodies
8.1.2.3 Purified Proteins
8.1.3 Performance of Top Players
8.1.4 Market Forecasts (2010-2015)
8.2 France
8.2.1 Market Performance (2005-2009)
8.2.2 Market Segmentation by Class
8.2.2.1 Recombinant Proteins
8.2.2.2 Monoclonal Antibodies
8.2.2.3 Purified Proteins
8.2.3 Performance of Top Players
8.2.4 Market Forecasts (2010-2015)
8.3 Italy
8.3.1 Market Performance (2005-2009)
8.3.2 Market Segmentation by Class
8.3.2.1 Recombinant Proteins
8.3.2.2 Monoclonal Antibodies
8.3.2.3 Purified Proteins
8.3.3 Performance of Top Players
8.3.4 Market Forecasts (2010-2015)
8.4 Spain
8.4.1 Market Performance (2005-2009)
8.4.2 Market Segmentation by Class
8.4.2.1 Recombinant Proteins
8.4.2.2 Monoclonal Antibodies
8.4.2.3 Purified Proteins
8.4.3 Performance of Top Players
8.4.4 Market Forecasts (2010-2015)
8.5 UK
8.5.1 Market Performance (2005-2009)
8.5.2 Market Segmentation by Class
8.5.2.1 Recombinant Proteins
8.5.2.2 Monoclonal Antibodies
8.5.2.3 Purified Proteins
8.5.3 Performance of Top Players
8.5.4 Market Forecasts (2010-2015)
8.6 Russia
8.6.1 Market Performance (2005-2009)
8.6.2 Market Segmentation by Class
8.6.2.1 Recombinant Proteins
8.6.2.2 Monoclonal Antibodies
8.6.2.3 Purified Proteins
8.6.3 Performance of Top Players
8.6.4 Market Forecasts (2010-2015)
8.7 Turkey
8.7.1 Market Performance (2005-2009)
8.7.2 Market Segmentation by Class
8.7.2.1 Recombinant Proteins
8.7.2.2 Monoclonal Antibodies
8.7.2.3 Purified Proteins
8.7.3 Performance of Top Players
8.7.4 Market Forecasts (2010-2015)

9. Asia Pacific
9.1 Japan
9.1.1 Market Performance (2005-2009)
9.1.2 Market Segmentation by Class
9.1.2.1 Recombinant Proteins
9.1.2.2 Monoclonal Antibodies
9.1.2.3 Purified Proteins
9.1.3 Performance of Top Players
9.1.4 Market Forecasts (2010-2015)
9.2 China
9.2.1 Market Performance (2005-2009)
9.2.2 Market Segmentation by Class
9.2.2.1 Recombinant Proteins
9.2.2.2 Monoclonal Antibodies
9.2.2.3 Purified Proteins
9.2.3 Performance of Top Players
9.2.4 Market Forecasts (2010-2015)
9.3 Australia
9.3.1 Market Performance (2005-2009)
9.3.2 Market Segmentation by Class
9.3.2.1 Recombinant Proteins
9.3.2.2 Monoclonal Antibodies
9.3.2.3 Purified Proteins
9.3.3 Performance of Top Players
9.3.4 Market Forecasts (2010-2015)
9.4 South Korea
9.4.1 Market Performance (2005-2009)
9.4.2 Market Segmentation by Class
9.4.2.1 Recombinant Proteins
9.4.2.2 Monoclonal Antibodies
9.4.2.3 Purified Proteins
9.4.3 Performance of Top Players
9.4.4 Market Forecasts (2010-2015)
9.5 India
9.5.1 Market Performance (2005-2009)
9.5.2 Market Segmentation by Class
9.5.2.1 Recombinant Proteins
9.5.2.2 Monoclonal Antibodies
9.5.2.3 Purified Proteins
9.5.3 Performance of Top Players
9.5.4 Market Forecasts (2010-2015)
9.6 Indonesia
9.6.1 Market Performance (2005-2009)
9.6.2 Market Segmentation by Class
9.6.2.1 Recombinant Proteins
9.6.2.2 Monoclonal Antibodies
9.6.2.3 Purified Proteins
9.6.3 Performance of Top Players
9.6.4 Market Forecasts (2010-2015)

List of figures:

Figure 2 1: Global Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 3 1: Complexity of Biopharmaceuticals
Figure 3 2: Sources of Biopharmaceuticals
Figure 4 1: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2000, 2009 & 2016
Figure 4 2: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
Figure 4 3: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
Figure 4 4: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
Figure 4 5: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs, (in US$)
Figure 4 6: Comparison of the Annual Cost of Therapy for Plaque Psoriasis Using Biopharmaceuticals and Small Molecule Drugs, (in US$)
Figure 4 7: Emerging Biopharmaceutical Market Forecast, (in Million US$), 2009 & 2015
Figure 4 8: Developed Biopharmaceutical Market Forecast, (in Million US$), 2009 & 2015
Figure 4 9: Total Number of New Biopharmaceuticals Approved by the FDA (in Numbers), 1982-2009
Figure 4 10: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval, (in %), 1993-2004
Figure 4 11: Global: Breakup of Small Molecule Drugs and Biopharmaceuticals in the Total Pharmaceutical Market & Phase III development, (%), 2009
Figure 4 12: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs, (in Million US$)
Figure 4 13: Research and Development Times Taken by Biopharmaceuticals to Reach the Market, (in Months), 1982-89,1990-94,1995-99, 2000-04, 2005-09
Figure 4 14: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)
Figure 4 15: Germany: Volume Share of Branded and Biosimilar Products in the Erythropoietins Alpha Market, (in %), September 2007 & April 2010
Figure 4 16: Current Medicare Payer Coverage for Monoclonal Antibodies
Figure 4 17: Performance of Biotech Stocks During the Financial Crisis, (in %), Jan 2008 to Dec 2008
Figure 5 1: Global: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 5 2: Global: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 5 3: Global: Biopharmaceutical Market: Sales Share by Country, (in %), 2009
Figure 5 4: Global: Biopharmaceutical Market Forecast: Sales Share by Country, (in %), 2015
Figure 5 5: Global: Biopharmaceutical Market: Sales Share by Indication, (in %), 2009
Figure 5 6: Global: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 5 7: Global: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 5 8: Global: Biopharmaceutical Market Forecast: Sales by Class, (in Million US$), 2010-2015
Figure 5 9: Global: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2010-2015
Figure 5 10: Global: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 5 11: Global: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 5 12: Global: Recombinant Proteins Market Forecast, (in Million US$), 2010-2015
Figure 5 13: Global: Recombinant Proteins Market Forecast: Sales Share by Class, (in %), 2015
Figure 5 14: Global: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 5 15: Global: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 5 16: Global: Monoclonal Antibodies Market Forecast, (in Million US$), 2010-2015
Figure 5 17: Global: Monoclonal Antibodies Market Forecast: Sales Share by Class, (in %), 2015
Figure 5 18: Global: Purified Proteins Market, (in Million US$), 2005-2009
Figure 5 19: Global: Purified Proteins Market: Sales Share by Class, (in %), 2009
Figure 5 20: Global: Purified Proteins Market Forecast, (in Million US$), 2010-2015
Figure 5 21: Global: Purified Proteins Market Forecast: Sales Share by Class, (in %), 2015
Figure 5 22: Global Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 6 1: US: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 6 2: US: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 6 3: US: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 6 4: US: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 6 5: US: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 6 6: US: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 6 7: US: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 6 8: US: Purified Proteins Market, (in Million US$), 2005-2009
Figure 6 9: US: Purified Proteins Market: Sales Share by Class, (in %), 2009
Figure 6 10: US: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 6 11: US: Biopharmaceutical Market Forecast, (in Million US$), 2009-2015
Figure 6 12: US: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 6 13: Canada: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 6 14: Canada: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 6 15: Canada: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 6 16: Canada: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 6 17: Canada: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 6 18: Canada: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 6 19: Canada: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 6 20: Canada: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 6 21: Canada: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 6 22: Canada: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 7 1: Mexico: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 7 2: Mexico: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 7 3: Mexico: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 7 4: Mexico: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 7 5: Mexico: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 7 6: Mexico: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 7 7: Mexico: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 7 8: Mexico: Purified Proteins Market, (in Million US$), 2005-2009
Figure 7 9: Mexico: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 7 10: Mexico: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 7 11: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 7 12: Brazil: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 7 13: Brazil: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 7 14: Brazil: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 7 15: Brazil: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 7 16: Brazil: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 7 17: Brazil: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 7 18: Brazil: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 7 19: Brazil: Purified Proteins Market, (in Million US$), 2005-2009
Figure 7 20: Brazil: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 7 21: Brazil: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 7 22: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 7 23: Argentina: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 7 24: Argentina: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 7 25: Argentina: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 7 26: Argentina: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 7 27: Argentina: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 7 28: Argentina: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 7 29: Argentina: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 7 30: Argentina: Purified Proteins Market, (in Million US$), 2005-2009
Figure 7 31: Argentina: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 7 32: Argentina: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 7 33: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 8 1: Germany: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 8 2: Germany: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 8 3: Germany: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 8 4: Germany: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 8 5: Germany: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 8 6: Germany: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 8 7: Germany: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 8 8: Germany: Purified Proteins Market, (in Million US$), 2005-2009
Figure 8 9: Germany: Purified Proteins Market: Sales Share by Class, (in %), 2009
Figure 8 10: Germany: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009

List of Tables:

Table 1 1: Global: Biopharmaceutical Market: Definition & Segmentation
Table 2 1: Global: Biopharmaceutical Market: SWOT Analysis
Table 2 2: Global: Recombinant Proteins Market Forecast: Sales by Class, (in Million US$), 2009 & 2015
Table 2 3: Global: Monoclonal Antibodies Market Forecast: Sales by Class, (in Million US$), 2009 & 2015
Table 2 4: Global: Purified Proteins Market Forecast: Sales by Class, (in Million US$), 2009 & 2015
Table 2 5: Global: Biopharmaceutical Market Forecast: Sales by Region, (in Million US$), 2009 & 2015
Table 3 1: Differences Between Small Molecule Drugs & Biopharmaceuticals
Table 3 2: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs
Table 4 1: Global: Top Ten Selling Drugs (Based on Origin), 2000
Table 4 2: Global: Top Ten Selling Drugs (Based on Origin), 2009
Table 4 3: Global: Top Ten Selling Drugs Forecast (Based on Origin), 2016
Table 4 4: Mode of Administration of Popular Biotech Drugs
Table 4 5: FDA: Total Number of Biopharmaceutical Approvals in 2009
Table 4 6: US and European Statistics of Branded Biopharmaceutical Products Facing Biosimilar Threat, (in Million US$), 2009
Table 5 1: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2005-2009
Table 5 2: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2010-2015
Table 5 3: Global: Biopharmaceutical Market: Sales by Indication, (in Billion US$), 2009
Table 5 4: Global: Contribution of Various Classes to Total Biopharmaceutical Growth, (in Million US$), 2009-2015
Table 5 5: Global: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 5 6: Global: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 5 7: Global: Recombinant Proteins Market Forecast: Sales by Class, (in %), 2010-2015
Table 5 8: Global: Recombinant Proteins Market Forecast: Sales Share by Class, (in %), 2010-2015
Table 5 9: Global: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 5 10: Global: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 5 11: Global: Humanized Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$), 2009
Table 5 12: Global: Chimeric Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$), 2009
Table 5 13: Global: Fully Human Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$), 2009
Table 5 14: Global: Murine Monoclonal Antibodies Market: Sales of Marketed Products, (in 000’ US$), 2009
Table 5 15: Global: Murine Monoclonal Antibodies in Phase-III Development
Table 5 16: Global: Chmeric Monoclonal Antibodies in Phase-III Development
Table 5 17: Global: Humanized Monoclonal Antibodies in Phase-III Development
Table 5 18: Global: Fully Human Monoclonal Antibodies in Phase-III Development
Table 5 19: Global: Immunotoxins in Phase-III Development
Table 5 20: Global: Monoclonal Antibodies Market Forecast: Sales by Class, (in Million US$), 2010-2015
Table 5 21: Global: Monoclonal Antibodies Market Forecast: Sales Share by Class, (in %), 2010-2015
Table 5 22: Global: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 5 23: Global: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 5 24: Global: Purified Proteins Market Forecast: Sales by Class, (in Million US$), 2010-2015
Table 5 25: Global: Purified Proteins Market Forecast: Sales Share by Class, (in %), 2010-2015
Table 5 26: Global: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 5 27: Global: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009
Table 5 28: Global: Biopharmaceutical Market; Sales Forecast of Top Biopharmaceuticals, (in Million US$), 2009 & 2016
Table 6 1: US: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 6 2: US: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 6 3: US: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 6 4: US: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 6 5: US: Purified Proteins Market: Sales by Class, 2005-2009
Table 6 6: US: Purified Proteins Market: Sales Share by Class, 2005-2009
Table 6 7: US: Biopharmaceutical Market: Sales of Top Players, (in US$), 2005-2009
Table 6 8: US: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009
Table 6 9: Canada: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 6 10: Canada: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 6 11: Canada: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 6 12: Canada: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 6 13: Canada: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 6 14: Canada: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009
Table 7 1: Mexico: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 7 2: Mexico: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 7 3: Mexico: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 7 4: Mexico: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 7 5: Mexico: Purified Proteins Market: Sales by Class (in Million US$), 2005-2009
Table 7 6: Mexico: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 7 7: Mexico: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009
Table 7 8: Brazil: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 7 9: Brazil: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 7 10: Brazil: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 7 11: Brazil: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 7 12: Brazil: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 7 13: Brazil: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 7 14: Brazil: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 7 15: Brazil: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009
Table 7 16: Argentina: Recombinant Proteins Market: Sales by Class, 2005-2009
Table 7 17: Argentina: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 7 18: Argentina: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 7 19: Argentina: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 7 20: Argentina: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 7 21: Argentina: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 7 22: Argentina: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009
Table 8 1: Germany: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 8 2: Germany: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 8 3: Germany: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 8 4: Germany: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 8 5: Germany: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 8 6: Germany: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 8 7: Germany: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 8 8: Germany: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009
Table 8 9: France: Recombinant Proteins Market: Sales by Class,(in Million US$), 2005-2009
Table 8 10: France: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 8 11: France: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 8 12: France: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 8 13: France: Purified Proteins Market: Sales by Class, 2005-2009
Table 8 14: France: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 8 15: France: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009
Table 8 16: Italy: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 8 17: Italy: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 8 18: Italy: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 8 19: Italy: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 8 20: Italy: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 8 21: Italy: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 8 22: Italy: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 8 23: Italy: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009
Table 8 24: Spain: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 8 25: Spain: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 8 26: Spain: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 8 27: Spain: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 8 28: Spain: Purified Proteins Market: Sales by Class, 2005-2009
Table 8 29: Spain: Purified Proteins Market: Sales Share by Class, 2005-2009
Table 8 30: Spain: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 8 31: Spain: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009
Table 8 32: UK: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 8 33: UK: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 8 34: UK: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 8 35: UK: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 8 36: UK: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 8 37: UK: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 8 38: UK: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 8 39: UK: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009
Table 8 40: Russia: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 8 41: Russia: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 8 42: Russia: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 8 43: Russia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 8 44: Russia: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 8 45: Russia: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 8 46: Russia: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 8 47: Russia: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009
Table 8 48: Turkey: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 8 49: Turkey: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 8 50: Turkey: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 8 51: Turkey: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 8 52: Turkey: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 8 53: Turkey: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 8 54: Turkey: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009
Table 9 1: Japan: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 9 2: Japan: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 9 3: Japan: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 9 4: Japan: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 9 5: Japan: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 9 6: Japan: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 9 7: Japan: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 9 8: Japan: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009
Table 9 9: China: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 9 10: China: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 9 11: China: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 9 12: China: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 9 13: China: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 9 14: China: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 9 15: China: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 9 16: China: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009
Table 9 17: Australia: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 9 18: Australia: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 9 19: Australia: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 9 20: Australia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 9 21: Australia: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 9 22: Australia: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 9 23: Australia: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009
Table 9 24: South Korea: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 9 25: South Korea: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 9 26: South Korea: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 9 27: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 9 28: South Korea: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 9 29: South Korea: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 9 30: South Korea: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 9 31: South Korea: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2005-2009
Table 9 32: India: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 9 33: India: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 9 34: India: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 9 35: India: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 9 36: India: Purified Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 9 37: India: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 9 38: India: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009
Table 9 39: Indonesia: Recombinant Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 9 40: Indonesia: Recombinant Proteins Market: Sales Share by Class, (in %), 2005-2009
Table 9 41: Indonesia: Monoclonal Antibodies Market: Sales by Class, (in Million US$), 2005-2009
Table 9 42: Indonesia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2005-2009
Table 9 43: Indonesia: Purified Proteins Market: Sales by Class, (in Million US$), 2005-2009
Table 9 44: Indonesia: Biopharmaceutical Market: Sales of Top Players, (in Million US$), 2005-2009
Table 9 45: Indonesia: Biopharmaceutical Market: Sales Share of Top Players, (in %) 2005-2009
Figure 8 11: Germany: Biopharmaceutical Market Forecast, (in Million US$), 2009-2015
Figure 8 12: Germany: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 8 13: France: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 8 14: France: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 8 15: France: Biopharmaceutical Market: Sales Share By Class, (in %), 2005-2009
Figure 8 16: France: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 8 17: France: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 8 18: France: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 8 19: France: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 8 20: France: Purified Proteins Market, (in Million US$), 2005-2009
Figure 8 21: France: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 8 22: France: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 8 23: France: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 8 24: Italy: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 8 25: Italy: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 8 26: Italy: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 8 27: Italy: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 8 28: Italy: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 8 29: Italy: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 8 30: Italy: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 8 31: Italy: Purified Proteins Market, (in Million US$), 2005-2009
Figure 8 32: Italy: Biopharmaceutical Market: Sales Share of top players, (in %), 2009
Figure 8 33: Italy: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 8 34: Italy: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 8 35: Spain: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 8 36: Spain: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 8 37: Spain: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 8 38: Spain: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 8 39: Spain: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 8 40: Spain: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 8 41: Spain: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 8 42: Spain: Purified Proteins Market, (in Million US$), 2005-2009
Figure 8 43: Spain: Purified Proteins Market: Sales Share by Class, (in %), 2009
Figure 8 44: Spain: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 8 45: Spain: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 8 46: Spain: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 8 47: UK: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 8 48: UK: Biopharmaceutical Market, Sales by Class, (in Million US$), 2005-2009
Figure 8 49: UK: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 8 50: UK: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 8 51: UK: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 8 52: UK: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 8 53: UK: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 8 54: UK: Purified Proteins Market, (in Million US$), 2005-2009
Figure 8 55: UK: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 8 56: UK: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 8 57: UK: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 8 58: Russia: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 8 59: Russia: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 8 60: Russia: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 8 61: Russia: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 8 62: Russia: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 8 63: Russia: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 8 64: Russia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 8 65: Russia: Purified Proteins Market, (in Million US$), 2005-2009
Figure 8 66: Russia: Purified Proteins Market: Sales Share by Class, (in %), 2009
Figure 8 67: Russia: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 8 68: Russia: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 8 69: Russia: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 8 70: Turkey: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 8 71: Turkey: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 8 72: Turkey: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 8 73: Turkey: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 8 74: Turkey: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 8 75: Turkey: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 8 76: Turkey: Purified Proteins Market, (in Million US$), 2005-2009
Figure 8 77: Turkey: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 8 78: Turkey: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 8 79: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 9 1: Japan: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 9 2: Japan: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 9 3: Japan: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 9 4: Japan: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 9 5: Japan: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 9 6: Japan: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 9 7: Japan: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 9 8: Japan: Purified Proteins Market, (in Million US$), 2005-2009
Figure 9 9: Japan: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 9 10: Japan: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 9 11: Japan: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 9 12: China: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 9 13: China: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 9 14: China: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 9 15: China: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 9 16: China: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 9 17: China: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 9 18: China: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 9 19: China: Purified Proteins Market, (in Million US$), 2005-2009
Figure 9 20: China: Purified Proteins Market: Sales Share by Class, (in %), 2009
Figure 9 21: China: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 9 22: China: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 9 23: China: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 9 24: Australia: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 9 25: Australia: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 9 26: Australia: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 9 27: Australia: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 9 28: Australia: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 9 29: Australia: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 9 30: Australia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 9 31: Australia: Purified Proteins Market, (in Million US$), 2005-2009
Figure 9 32: Australia: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 9 33: Australia: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 9 34: Australia: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 9 35: South Korea: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 9 36: South Korea: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 9 37: South Korea: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 9 38: South Korea: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 9 39: South Korea: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 9 40: South Korea: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 9 41: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 9 42: South Korea: Purified Proteins Market, (in Million US$), 2005-2009
Figure 9 43: South Korea: Purified Proteins Market: Sales Share by Class, (in %), 2009
Figure 9 44: South Korea: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 9 45: South Korea: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 9 46: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 9 47: India: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 9 48: India: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 9 49: India: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 9 50: India: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 9 51: India: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 9 52: India: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 9 53: India: Purified Proteins Market, (in Million US$), 2005-2009
Figure 9 54: India: Purified Proteins Market: Sales Share by Class, (in %), 2009
Figure 9 55: India: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 9 56: India: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 9 57: India: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 2015
Figure 9 58: Indonesia: Biopharmaceutical Market, (in Million US$), 2005-2009
Figure 9 59: Indonesia: Biopharmaceutical Market: Sales by Class, (in Million US$), 2005-2009
Figure 9 60: Indonesia: Biopharmaceutical Market: Sales Share by Class, (in %), 2005-2009
Figure 9 61: Indonesia: Recombinant Proteins Market, (in Million US$), 2005-2009
Figure 9 62: Indonesia: Recombinant Proteins Market: Sales Share by Class, (in %), 2009
Figure 9 63: Indonesia: Monoclonal Antibodies Market, (in Million US$), 2005-2009
Figure 9 64: Indonesia: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2009
Figure 9 65: Indonesia: Purified Proteins Market, (in Million US$), 2005-2009
Figure 9 66: Indonesia: Biopharmaceutical Market: Sales Share of Top Players, (in %), 2009
Figure 9 67: Indonesia: Biopharmaceutical Market Forecast, (in Million US$), 2010-2015
Figure 9 68: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class, (in %), 201